Restructuring in the Japanese pharma industry

For years investment bankers had visions of mega fees flowing in from pharma company restructuring deals in Japan. It was never a question of “Will the deals come?” The only question was “When?” Today most of the deal makers have moved on to greener (as in money) pastures where the deal flow is robust (as in outbound investments).

Not much is going on in the Japan pharma industry, says P Reed Maurer, long time pharma industry watcher who is president of International Alliances Limited, in his regular exclusive insight for The Pharma Letter.

With hindsight let’s review what did happen in Japan and what is inevitable, that is what will or must transpire while leaving aside the question of when.